Niraparib-induced STAT3 inhibition increases its antitumor effects.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Poly(ADP-ribosyl)ation polymerase inhibitors (PARPis) are promising cancer therapies, particularly for BRCA-mutated cancers.
• Olaparib (PARPi) is approved for specific deficiencies, while Niraparib is approved for ovarian cancer regardless of DNA repair status.
• The mechanism of Niraparib's efficacy in non-deficient cancers and its potential in pancreatic ductal adenocarcinoma (PDAC) remain unclear.

Purpose of the Study:

• To investigate the efficacy of Niraparib compared to Olaparib in ovarian and PDAC tumor cells.
• To elucidate the molecular mechanism underlying Niraparib's anti-tumor activity, focusing on STAT3 signaling.
• To explore Niraparib's potential as a therapeutic agent for PDAC patients irrespective of BRCA mutation status.

Main Methods:

• In vitro cell growth inhibition assays comparing Niraparib and Olaparib.
• Analysis of STAT3 activity and downstream gene expression in cancer cell lines and patient tumors.
• Investigation of the role of SRC tyrosine kinase in Niraparib's mechanism of action.
• Assessment of Niraparib's efficacy in models with and without BRCA mutations.

Main Results:

• Niraparib demonstrated superior inhibition of ovarian and PDAC tumor cell growth compared to Olaparib, irrespective of BRCA mutational status.
• Niraparib, unlike Olaparib, inhibited STAT3 activity and regulated apoptosis-associated STAT3 downstream genes.
• Niraparib's mechanism involves the inhibition of phosphorylated STAT3 (pSTAT3) through interference with SRC tyrosine kinase.
• Overexpression of a constitutively active STAT3 mutant rescued Niraparib-induced apoptosis, confirming STAT3's role.

Conclusions:

• Niraparib exhibits potent anti-tumor activity in ovarian and PDAC cells, independent of BRCA mutation status.
• Niraparib's efficacy is mediated through the inhibition of STAT3 signaling via SRC tyrosine kinase.
• These findings support the potential of Niraparib as a therapeutic option for a broader range of PDAC patients, including those without BRCA mutations.